All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact

Brought to you by

Scientific Education Support logo

The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Johnson & Johnson, Kura Oncology, Roche, Syndax and Thermo Fisher, and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

TypesTherapeuticsCongressesTrialsExpert OpinionsEducational ResourcesDRUG UPDATES
2018-12-07T10:14:21.000Z

Andreas Burchert | ASH 2018 | Key highlights of the Sormain trial

By Cynthia Umukoro
Featured
Andreas Burchert
Dec 7, 2018
Share:

Bookmark this article

At the 60th American Society of Hematology (ASH) Annual Meeting, Andreas Burchert from the University of Marburg, Germany, discusses the study findings of the Sormain trial, which is evaluating sorafenib as maintenance therapy after allogeneic stem cell transplantation for patients with FLT3-ITD–positive acute myeloid leukemia.

Andreas Burchert | ASH 2018 | Key highlights of the Sormain trial

More about...
AML-related mutationsASH 2018FLT3-ITDSorafenibSORMAIN

Your opinion matters

HCPs, what is your preferred format for educational content on the AML Hub?
29 votes - 43 days left ...

Related articles

Add bookmark

Editorial theme │ Maintenance therapy for AML

Maintenance therapy has been proven very efficacious at improving long-term patient outcomes and reducing relapse in the acute lymphoblastic leukemia (ALL) setting. Thus, research into the role of...

Dec 10, 2019
Add bookmark

Editorial theme │ Maintenance therapy for AML

Maintenance therapy has been proven very efficacious at improving long-term patient outcomes and reducing relapse in the acute lymphoblastic leukemia...

Dec 10, 2019
Add bookmark

Sorafenib in combination with azacitidine in older patients with FLT3-ITD mutated acute myeloid leukemia

The combination of sorafenib and azacitidine is well tolerated and effective in older patients with newly diagnosed FLT3-ITD mutated AML

Jul 31, 2018
Add bookmark

Sorafenib in combination with azacitidine in older patients with FLT3-ITD mutated acute myeloid leukemia

The combination of sorafenib and azacitidine is well tolerated and effective in older patients...

Jul 31, 2018

Newsletter

Subscribe to get the best content related to AML delivered to your inbox